Research that is free to access for all investors. Companies commission these providers to write research about them.
Brokers who write research on their corporate clients and make it available through our main bundle offering.
Research that is paid for directly by asset managers. Only accessible to institutional investors permissioned for access.
Event in Progress:
Research Tree provides access to ongoing research coverage, media content and regulatory news on Medley, Inc.. We currently have 0 research reports from 0 professional analysts.
A positive FY24E update from Marlowe confirms it is trading in line with expectations (£403m revenue, £49m adj. EBITDA), with a better-than-expected year-end net debt position (£177m vs £180m forecast) owing to strong cash generation and working capital improvements. Marlowe also announces that it has now received all necessary regulatory approvals for its disposal of certain Governance, Risk and Compliance (GRC) assets to Inflexion Private Equity, with the transaction expected to complete on 31
Companies: Marlowe Plc
Cavendish
A resilient performance in FY24 by Braemar saw revenue maintained at £152.8m (FY23: £152.9m), a strong performance given the 51% increase in revenue the previous year. Overall fixtures were up 8% and the forward order book has increased by 47% to £65.3m ($82.6m). The focus on shipbroking and securities, having disposed of non-core activities and adding to shipbroking operations, is proving successful with increasingly diversified revenue across shipping segments. The initial objective of sustain
Companies: Braemar PLC
Companies: IXI GETB ONC CLX
Companies: FOUR PCIP FEN MRL KRM HDD CUSN
Companies: BMS SOLI IXI CUSN
IXICO has reported interim results for the 6-months to March 2024. The company generated revenues of £2.5m, down 21% YoY reflecting the challenging market conditions which IXICO has previously discussed. Given the market conditions, the period saw IXICO’s order book decrease. However, the company expects a stronger H2/24 noting turn in market conditions and progress on contracting new business, which should support revenues in H2/24 and beyond. The company has also completed cost reduction progr
Companies: IXICO Plc
Samarkand Group plc (SMK ASE) has today reported a trading update for the 12 months ending March 31st 2024 (FY 2024). SMK, a cross-border eCommerce technology, services, and consumer brand group is undergoing turnaround. It is expanding revenue outside China, which had been impacted by COVID and now consumer price pressure and competition, through selling higher margin wholly owned skincare and wellness brands in Europe. SMK has reduced internal costs and today reports FY 2024 EBITDA losses redu
Companies: Samarkand Group Plc
VSA Capital
A positive FY24 update reiterates the inherent reliability of its business. Both revenues (up 12% at c £136m) and EBITDA are expected to come in ahead of market expectations, adj. PBT in line. The latter reflects relatively subdued corporate finance M&A volumes and expenses related to investment in its teams and IT support. According to the update both divisions grew materially y-o-y on the back of acquisitions and organic growth. Business recovery and advisory was c 7% up, property advisory an
Companies: Begbies Traynor Group plc
Equity Development
Shore Capital
IXICO has announced it has signed a contract with the Global Alzheimer’s Platform (GAP) Foundation to support the foundation’s Bio-Hermes-2 trial. The contract is worth over £1m over a 48-month period; however, we believe the value to IXICO will be greater than this ‘headline’ amount due to the increased visibility and wider recognition of the company’s technology within the Alzheimer’s disease clinical development community. IXICO participated and presented data from the initial Bio-Hermes tria
This morning's announcement from CODE marks a new stage in the development of its Business Solutions activity, which is now launched into the market under a fresh brand, Counter. In this new personification, the company is marketing a highly focused, stand-alone activity which will enable its clients to incubate talent with senior leadership, with the option to retain the Northcoders team once a specific project is completed. Counter will sit alongside CODE's successful and profitable Bootcamps
Companies: Northcoders Group PLC
WHIreland
The focus of Hardman & Co Research is on the nine quoted Infrastructure Investment Companies (IICs) and on the 22 Renewable Energy Infrastructure Funds (REIFs): the stocks analysed are all members of the Association of Investment Companies (AIC). We are updating our publication of January 2023, assessing both the lacklustre share price performances during 2023 and the key issues, including interest rates, inflation and power prices. As a 31-strong group, its combined market capitalisation is no
Companies: AEIT ROOF DGI9 INPP GSF SEIT USFP HICL ORIT BSIF TRIG NESF SEQI HEIT GRP GCP FSFL 3IN AERI PINT RNEW BBGI GSEO DORE TENT GRID CORD HGEN AEET
Hardman & Co
In this note we look at the gap between perception and reality in the UK equity market, the opportunities and threats in the economic and market outlook, and the emerging consensus that the valuation discount versus other major markets is at or close to an inflection point. We consider the benefits of UK equity strategies both for income investors and for those seeking exposure to the higher growth potential of smaller and mid-cap companies.
Companies: ATS MRCH SCP SHRS LWDB JUGI MINI
Capital Access Group
The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. For the second year running, apart from global economic influences affecting world markets, performance in 2023 was dented by the capital-intensive nature of the sector. The HHI fell 3.7%, to 483.8, underperforming the main London markets – FTSE 100 (+3.8%) and FTSE All-Share (3.8%) but outperforming the FTSE AIM All-Share Index (
Companies: TXG ETXPF NDVA TSVT BCOW Z29 TXG NCYT GNS SUN AMS OMG APH EKF EAH IMM AGL DEMG AGY TSTL IPO GDR TRX HVO CTEC OXB DEST VLG IXI VAL INDV AGR AVCT BAI 123F IMCR BCOW
Canaccord Genuity
Share: